Causes for Loss of Effectiveness of Psoriasis Agents: Meeting Highlights from a National Dermatology Conference
Psoriasis, an inflammatory, autoimmune disorder, causes predominately joint & skin problems that are characterized by scaling and erythematous plaques that can be painful or severely pruritic and can have a significant negative impact on quality of life for patients with this condition. Unfortunately, psoriasis is often undertreated & those who are receiving treatment are not satisfied; in fact, a large number of those with moderate-to-severe-psoriasis are either untreated or are only using topical treatments. In this CME Outfitters Meeting Highlight Series, Bruce E. Strober, MD, PhD, and Joel M. Gelfand, MD, MSCE, translate insights & recommendations about current & emerging psoriasis treatment, monitoring of patients on biologics, management of comorbidities, and quality of life. You’ll get the scoop on the mechanism of action, efficacy, & safety of available and newly emerging biologics for psoriasis, as well as updates on comorbidities in patients with psoriasis.
This activity is supported by an educational grant from Lilly.